Rhenium-SCT®


The global incidence of non-melanoma skin cancers has been drastically increasing over the past few decades. Depending on the source, it is estimated that there are over 5 million non-melanoma skin cancer cases reported globally each year. About 80% of non-melanoma skin cancers are basal cell carcinomas or squamous cell carcinomas. According to some statistics there has been a 300 percent increase in skin cancer incidence since 1994 and presently one in every three cancers diagnosed is a skin cancer.

The Rhenium-SCT® (Skin Cancer Therapy) is a specialized state-of-the-art brachytherapy utilizing the
radioisotope Rhenium-188, a beta-emitter which in this case is used for the treatment of basal and squamous cell carcinomas of the skin.

painless
Painless

The Rhenium-SCT® is a painless therapy with no anaesthesia needed. Especially good for elderly patients, patients with allergies and patients with multiple morbidities or low tolerance to pain.

painless
Single Session

The Rhenium-SCT® is a single-session treatment in most all cases.

painless
Non-Invasive

The Rhenium-SCT® is a medical procedure which is non-invasive. A procedure is considered non-invasive when no break or cut in the skin is created. This means no stitches or the possibility of secondary infection.

painless
Personalised

The Rhenium-SCT® is a precise, personalised therapy that is only applied to the area needed to treat. This means that no unnecessary healthy tissue is damaged either in the depth or outside of the safety border.

painless
Short Treatment Duration

Easy and practical thank the simple application and short treatment duration.

painless
Aesthetic

Sensational aesthetic results with little or no scarring, considerably fast healing period, no stress treatment, restored functionality.

painless
Painless

The Rhenium-SCT® is a painless therapy with no anaesthesia needed. Especially good for elderly patients, patients with allergies and patients with multiple morbidities or low tolerance to pain.

painless
Single Session

The Rhenium-SCT® is a single-session treatment in most all cases.

painless
Non-Invasive

The Rhenium-SCT® is a medical procedure which is non-invasive. A procedure is considered non-invasive when no break or cut in the skin is created. This means no stitches or the possibility of secondary infection.

painless
Personalised

The Rhenium-SCT® is a precise, personalised therapy that is only applied to the area needed to treat. This means that no unnecessary healthy tissue is damaged either in the depth or outside of the safety border.

painless
Short Treatment Duration

Easy and practical thank the simple application and short treatment duration.

aesthetic
Aesthetic

Sensational aesthetic results with little or no scarring, considerably fast healing period, no stress treatment, restored functionality.


What is Rhenium-SCT®?


What is Rhenium-188?

Rhenium is one of the rarest elements on the earth’s surface. Rhenium-188 is a so-called beta-emitter isotope with excellent therapeutic advantages.
Rhenium-188 has a half-life of about 17 hours which means that it decays continuously while mainly emitting beta-radiation.
The penetration range of Rhenium-188’s beta-radiation is very shallow in human tissue, up to 3mm in depth.

This makes Rhenium-188 ideal for targeted treatment of superficial skin cancer types, like most non-melanoma skin cancers
The main objective of the Rhenium-SCT® is to be a painless, personalised, non-invasive therapy targeting and destroying cancer cells in the area needed to treat.

The medical working principle of the Rhenium-SCT® or epidermal radioisotope therapy is based on the local direct cell-killing effect of the beta-radiation,
which triggers both the local death of cells and local reactions of the immune system of the body to repair itself.

Transversal view of the skin.

How does the Rhenium-SCT® work?


The Oncobeta® Applicator

The Oncobeta® Applicator is a specially designed application device which enables the clinician to apply the Rhenium-SCT® compound in a homogenic manner to the area needed to treat.

The specially designed shielding of the applicator consists of ideal materials for protection which has gone through numerous
and extensive testing. The Oncobeta® Applicator is significantly designed to protect both the clinician and patient.

Rhenium-SCT Applicator

The Oncobeta® Applicator

The Rhenium-188 Compound

Rhenium-188 is bound to a fluid matrix or “compound” in order to enable an application precisely over the tumour.

The Rhenium-188-Compound is filled in so called carpoules which include a specially designed brush for precise application.

The Carpoules are loaded into the special Oncobeta® applicator for safe handling and efficient usage.

The lesion or the area needed to treat is first covered with a special protective foil.

During the Rhenium-SCT®, the physician is able to apply the exact needed amount of the Rhenium-188-Compound accurately and efficiently utilizing the specifically developed mechanical control. This way the compound is applied homogeneously and precisely over the tumour or area needed to treat.

Carpoules filled with Rhenium-188 Compound

Application of Rhenium-188-Compound with Applicator

Steps of the Rhenium-SCT®

1

The dermato-oncologist or skin cancer specialist marks the area needed to treat with the Rhenium-SCT® using a dermatological pen.

2

The area needed to treat is first covered with a special protective foil. The Rhenium-188-Compound is then applied on top of the special foil, over the marked area of treatment with the Oncobeta® Applicator. The foil and compound are to stay in place until the end of the procedure.

3

The treatment takes approximately 30 to 180 minutes after the compound has been applied on the area needed to treat. The patient sits or lays comfortably while the Rhenium-188 compound works on the lesion.The protective foil and the dry Rhenium-188-Compound are removed after the designated treatment time.

4

After Care: In general, there is no special aftercare needed. The dead tumour cells are gradually disposed of by the body and replaced with new healthy cells.

Which cases can be treated with Rhenium-SCT®?

The Rhenium-SCT® is approved in Europe for the treatment of basal and squamous cell carcinomas of the skin.

In general, the Rhenium-SCT® can be applied to any location on the body. It can be applied to single and/or multiple lesions of almost any shape or size in just one session. It is also suitable for patients of any age as well as patients with previously treated or complicated lesions.

The Rhenium-SCT® is not recommended for minors or pregnant patients.

Before and After Treatment Comparison